Market Spotlight: Tuberculosis (TB)
Market Spotlight: Tuberculosis (TB)
$1,318.00
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition de
Key Takeaways
- KEY TAKEAWAYS Datamonitor Healthcare estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
- Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being intradermal, topical, and intravenous formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with one drug being tested in an intramuscular formulation.
- High-impact upcoming events for drugs in the TB space comprise topline Phase II trial results for GSK3036656, and topline Phase I/II trial results for OPC-167832.
- The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 18.5%, and the average probability a drug advances from Phase III is 60.6%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for TB have been in the early and midphases of development, with 74% of trials in Phase I–II, and only 26% in Phase III–IV.
- South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
- GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Patient subtypes
8 Symptoms
8 Risk factors
8 Diagnosis
9 TREATMENT
9 Anti-TB drugs
10 Surgery
11 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
24 KEY UPCOMING EVENTS
25 KEY REGULATORY EVENTS
25 CHMP Recommends Approval Of Extended Indication For Deltyba
25 Nitrosamine Concerns Spur Precautionary Testing Of Rifampicin In EU
25 The FDA’s Latest Nitrosamine Decision Weighs Tuberculosis Versus Cancer Risk
25 Hope For Price Flexibility After India Pretomanid Go-Ahead
26 PROBABILITY OF SUCCESS
27 LICENSING AND ASSET ACQUISITION DEALS
27 PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For $591M
27 Amgen Licenses TB Candidate To MDGH
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
31 Recent events
32 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
13 Figure 1: Global trends in incident cases of tuberculosis, 2018–27
19 Figure 2: Overview of pipeline drugs for tuberculosis in the US
19 Figure 3: Pipeline drugs for tuberculosis, by company
20 Figure 4: Pipeline drugs for tuberculosis, by drug type
20 Figure 5: Pipeline drugs for tuberculosis, by classification
24 Figure 6: Key upcoming events in tuberculosis
26 Figure 7: Probability of success in the antibacterial, mycobacterial, or fungal pipeline
28 Figure 8: Clinical trials in tuberculosis
28 Figure 9: Top 10 drugs for clinical trials in tuberculosis
29 Figure 10: Top 10 companies for clinical trials in tuberculosis
29 Figure 11: Trial locations in tuberculosis
30 Figure 12: Tuberculosis trials status
31 Figure 13: Tuberculosis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Global incident cases of tuberculosis, 2018–27
14 Table 2: Global incident cases of tuberculosis with HIV, 2018
15 Table 3: Global incident cases of MDR/RR tuberculosis, 2018
17 Table 4: Marketed drugs for tuberculosis
21 Table 5: Pipeline drugs for tuberculosis in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Cystic Fibrosis 
Sign up to the